Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 8/20 | 0.55 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.48 |
| ▸ | HINT1 | P49773 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409710 | 1.00 | NT5E (0.55) | NT5EHSP90B1HINT1ADORA3RNASEL | |
| SCHEMBL12300490 | 0.88 | ADORA3 (0.60) | NT5EADORA3RNASELADORA1P2RY1 | |
| SCHEMBL16409711 | 0.88 | ADORA3 (0.60) | NT5EADORA3RNASELADORA1P2RY1 | |
| SCHEMBL12300422 | 0.84 | NT5E (0.56) | NT5EHINT1 | |
| SCHEMBL12150802 | 0.79 | HSP90B1 (0.46) | NT5EHSP90B1HINT1ADORA3ADORA2A | |
| SCHEMBL12746912 | 0.79 | HSP90B1 (0.46) | NT5EHSP90B1HINT1ADORA3ADORA2A | |
| SCHEMBL1527213 | 0.79 | ADORA2A (0.66) | NT5EADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL12300482 | 0.79 | ADORA2A (0.66) | NT5EADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL12150807 | 0.79 | ADORA2A (0.66) | NT5EADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL12031300 | 0.79 | ADORA2A (0.66) | NT5EADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | NT5E 203/4885HSP90B1 1694/4885HINT1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.